NEM vs SGMO · P/E 14, rev $13.43B vs rev $57.8M
Newmont Goldcorp Corp (NEM) versus Sangamo Therapeutics Inc (SGMO) — a side-by-side from cached financials, not a winner call.
Newmont Goldcorp Corp (NEM) is a gold company listed on NYSE.
Sangamo Therapeutics Inc (SGMO) is a biotechnology company listed on NASDAQ.
Latest reported NEM revenue for 2026-06-30 was $13.43B. Net income was $5.46B. Revenue was up 83.7% from 2026-03-31 to 2026-06-30. NEM currently screens at market cap $112.81B and trailing P/E 13.7.
Latest reported SGMO revenue for 2024-12-31 was $57.8M. Net income was -$97.9M. Revenue was down 67.2% from 2023-12-31 to 2024-12-31. SGMO currently screens at market cap $74.6M.
NEM currently screens at market cap $112.81B and trailing P/E 13.7. SGMO currently screens at market cap $74.6M.
Not investment advice. Open the NEM and SGMO stock pages for the full models.
Not investment advice.